|
業務類別
|
Biotechnology |
|
業務概覽
|
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products andclinical candidates designed to target different cell types within the body. |
| 公司地址
| 177 E Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105 |
| 電話號碼
| +1 626 304-3400 |
| 傳真號碼
| +1 626 304-3401 |
| 公司網頁
| https://www.arrowheadpharma.com |
| 員工數量
| 711 |
| Dr. Christopher Anzalone,PhD |
Chairman of the Board, Chief Executive Officer and President |
美元 981.05K |
27/01/2026 |
| Mr. James Hamilton |
Chief of Discovery and Translational Medicine |
美元 617.51K |
29/01/2025 |
| Mr. Patrick C. O'Brien |
Chief Operating Officer, General Counsel and Corporate Secretary |
美元 653.94K |
29/01/2025 |
| Mr. Daniel Apel |
Chief Financial Officer and Principal Accounting Officer |
美元 232.21K |
25/11/2025 |
|
|
| Dr. Michael S. Perry, PhD |
Independent Director |
27/01/2026 |
| Dr. Christopher Anzalone,PhD |
Chairman of the Board, Chief Executive Officer and President |
27/01/2026 |
| Dr. Mauro Ferrari, PhD |
Independent Director |
27/01/2026 |
| Dr. Adeoye Olukotun, M.D.,M.P.H. |
Independent Director |
27/01/2026 |
| Dr. Hongbo Lu, PhD |
Independent Director |
27/01/2026 |
| Mr. William D. Waddill |
Lead Independent Director |
27/01/2026 |
| Ms. Victoria Vakiener |
Independent Director |
27/01/2026 |
|
|
|
|
